Xilio Therapeutics, Inc. (XLO)
9.00
+0.09
(+1.01%)
USD |
NASDAQ |
Sep 09, 14:01
Xilio Therapeutics Debt to Equity Ratio : 0.0872 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0872 |
| March 31, 2026 | 0.0915 |
| December 31, 2025 | 0.1971 |
| September 30, 2025 | -0.8972 |
| June 30, 2025 | 1.070 |
| March 31, 2025 | 0.735 |
| December 31, 2024 | 0.4627 |
| September 30, 2024 | 0.4012 |
| June 30, 2024 | 0.2598 |
| March 31, 2024 | 0.3471 |
| December 31, 2023 | 0.3408 |
| September 30, 2023 | 0.274 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.2495 |
| March 31, 2023 | 0.2136 |
| December 31, 2022 | 0.1899 |
| September 30, 2022 | 0.1591 |
| June 30, 2022 | 0.1404 |
| March 31, 2022 | 0.1228 |
| December 31, 2021 | 0.1118 |
| September 30, 2021 | 0.2391 |
| June 30, 2021 | 0.2043 |
| March 31, 2021 | 0.1715 |
| December 31, 2020 | -4.066 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cue Biopharma, Inc. | 3.813 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 154.25M |
| Total Liabilities (Quarterly) | 81.99M |
| Shareholders Equity (Quarterly) | 72.26M |
| Current Ratio | 4.254 |
| Net Debt Paydown Yield | 0.50% |